http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#Head
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#assertion
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#provenance
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#pubinfo
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#assertion
http://purl.obolibrary.org/obo/DOID_12700
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_12700
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01200
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
http://www.w3.org/2000/01/rdf-schema#label
bromocriptine mesylate tablets usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactin secreting adenomas reduction tumor size bromocriptine mesylate tablets usp are indicated in the treatment of acromegaly bromocriptine mesylate tablets usp therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 5 or more in approximately one half of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets usp offers potential benefit before the effects of irradiation are manifested bromocriptine mesylate tablets usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinson s disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets usp therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence and or severity of adverse reactions associated with long term levodopa therapy such as abnormal involuntary movements e g dyskinesias and the marked swings in motor function on off phenomenon continued efficacy of bromocriptine mesylate tablets usp therapy during treatment of more than two years has not been established data are insufficient to evaluate potential benefit from treating newly diagnosed parkinson s disease with bromocriptine mesylate tablets usp studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate tablets usp treated patients than in levodopa carbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets usp therapy
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01200
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#provenance
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#pubinfo
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig
http://purl.org/nanopub/x/hasSignature
bzsE91bAxZtKLFVBo/2OE375nP1vuZEesqcoYadRbGnw8rnRpem8ZYluEHTdo892vmWldZPtsUTeR+uipGFDZI48JI6EehI79vuoDYJJeqvQ5PnRv25K63Ty6EtXQ453MD4P2gb90w75HW6NF4xw/mtsjMp3+s4ZleIQWePzEEw=
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
http://purl.org/dc/terms/created
2021-07-03T13:13:12.279+02:00
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs